An official website of the United States government.

This is not the current EPA website. To navigate to the current EPA website, please go to www.epa.gov. This website is historical material reflecting the EPA website as it existed on January 19, 2021. This website is no longer updated and links to external websites and some internal pages may not work. More information »

Endangered Species

Draft National Level Listed Species Biological Evaluation for Propazine

In November 2020, EPA released the draft Biological Evaluation (BE) assessing risks to listed species from labeled uses of propazine. Listed species refers to those that are federally listed as endangered or threatened, as well as experimental populations and those species that are proposed and candidates for listing. The draft BE was conducted according to the Revised Method for National Level Listed Species Biological Evaluations of Conventional Pesticides.

The Revised Method described in this document incorporates:

  • Recommendations from the National Research Council of the National Academy of Sciences (NAS);
  • EPA’s “lessons learned” during the first three pilot BEs;
  • Public comments provided through stakeholder meetings, the docket on the draft BEs for chlorpyrifos, diazinon and malathion, and the docket on the proposed Revised Method;
  • Comments received during consultation with federally recognized tribes; and
  • Input provided by U.S. Fish and Wildlife Service, National Marine Fisheries Service and the US Department of Agriculture.

The Draft BE for atrazine is provided below. The models and tools used in triazine BEs can be found here.

Commenters are instructed to post comments to the BE docket (see EPA-HQ-OPP-2020-0514 at www.regulations.gov). The docket will be open for comment for 60 days after the Federal Register Notice (FRN) (FRL: 10015-77) announcing the availability of the draft BEs. View the prepublication notice of the biological evaluation for atrazine, simazine, and propazine. Additional information for commenters, including specific aspects of the draft BEs for which the EPA is seeking comment, will be available in the FRN.

On this page:

Draft Propazine Executive Summary (DOCX)(5 pp, 53 K)

Chapter 1: Draft Propazine Problem Formulation (DOCX)(8 pp, 51 K)

Attachments

Top of Page

Appendices

Top of Page

Chapter 2: Draft Propazine Effects Characterization (DOCX)(26 pp, 196 K)

Attachments

Appendices

Top of Page

Chapter 3: Draft Propazine Exposure Characterization (DOCX) (21 pp, 774 K)

Attachments

Appendices

Top of Page

Chapter 4: Draft Propazine Effects Determinations (DOCX)(13 pp, 98 K)

Attachments

Appendices

Top of Page